Gershon Capital is a Swiss early stage healthcare venture and private equity fund established in 2009, Emergent Life Sciences Fund with $3.15 B AUM, that provides a full suite of transatlantic financial and strategic solutions for emerging life science portfolio companies that possess innovative technologies and strong commercial potential.
The firm is a team of 32 people that provides direct investment, equity and debt syndicated financing, and M&A advisory for early stage life science companies.
We work with the highest quality companies and syndicate deals to the most prominent institutional investors in Europe, the Middle East, Asia, and the U.S. alongside our direct investment.
Medical, Legal, Regulatory & Operational Expertise
We leverage 20 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis defines our and due diligence process and gives investors a high level of confidence that our portfolio companies we work with will be successful.
Strong Relationships & Professional Networks
Our long standing relationships and professional affiliations with many of the most respected institutional investment funds, academic centers and industry leaders allows us to provide high level strategic consulting, technical advisory services, and deal syndication.
Vertically Integrated Partnerships
Our strong partnership with several prominent investment banks make us a fully vertically integrated investment firm, offering a broad array of capital raising solutions and financial advisory services for healthcare and life sciences companies.
Global Access to Capital and Financing
We believe that global access to capital and financing is critical for our companies and counterparties who are looking for efficient private placement, licensing, royalty monetization, and M&A transactions. Our headquarters are in New York, with affiliate offices in Zurich, London,, and Beijing. And our integrated networks throughout these geographies allows us to access over 300 institutional, strategic, and high net worth investors and family funds.
Non-Profit Investments
Gershon Capital is committed to social entrepreneurship and advancement of socially directed R&D and clinical research in countries throughout the world. Gershon Capital is proud to invest in companies that advances socially important goals in healthcare. As part of this process Gershon Capital works side by side as a financial and strategic investor with the National Institute for Science, Biotechnology, and Medical Research, a non-profit organization dedicated to advancing life saving healthcare policy and advancing the discovery of innovative healthcare products that will serve underserved patient communities.